Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: Long-term follow-up

Annals of the Rheumatic Diseases

Volumn 67, Issue 11, 2008, Pages 1567-1569

  Molloy, E S ^a   Langford, C A ^a   Clark, T M ^a   Gota, C E ^a   Hoffman, G S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; TUMOR NECROSIS FACTOR ANTIBODY;

ADOLESCENT; ADULT; AMINOTRANSFERASE BLOOD LEVEL; AORTA ARCH SYNDROME; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DIARRHEA; DISEASE CONTROL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HISTOPLASMOSIS; HUMAN; HYPERTENSION; INFECTION; LOW DRUG DOSE; MALE; NAUSEA; PRIORITY JOURNAL; RELAPSE; REMISSION; SIDE EFFECT; TREATMENT RESPONSE; VIRUS INFECTION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PREDNISONE; RECEPTORS, TUMOR NECROSIS FACTOR; RECURRENCE; RETROSPECTIVE STUDIES; TAKAYASU ARTERITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 54349085648     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2008.093260     Document Type: Article

References (11)

1. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med 1994;120:919-29.
2. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007;56:1000-9.
3. Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 2005;34(Suppl 1):34-8.
4. Tripathy NK, Chauhan SK, Nityanand S. Cytokine mRNA repertoire of peripheral blood mononuclear cells in Takayasu's arteritis. Clin Exp Immunol 2004;138:369-74.
5. Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford) 2006;45:545-8.
6. Tripathy NK, Gupta PC, Nityanand S. High TNF-α and low IL-2 producing T cells characterize active disease in Takayasu's arteritis. Clin Immunol 2006;118:154-8.
7. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004;50:2296-304.
8. Della Rossa A, Tavoni A, Merlini G, Baldini C, Sebastiani M, Lombardi M, et al. Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent? Rheumatology (Oxford) 2005;44:1074-5.
9. Karageorgaki ZT, Mavragani CP, Papathanasiou MA, Skopouli FN. Infliximab in Takayasu arteritis: a safe alternative? Clin Rheumatol 2007;26:984-7.
10. Tanaka F, Kawakami A, Iwanaga N, Tamai M, Izumi Y, Aratake K, et al. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern Med 2006;45:313-6.
11. Tato F, Rieger J, Hoffmann U. Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. Int Angiol 2005;24:304-7.